Table 2.
Overview of the main included sarcoma subtypes and controls.
| Sarcoma subtype/group | Included in DKFZ Classifier | Proportion predicted to correct methylation class (%) |
|---|---|---|
| Adamantinoma (n = 19) | No | — |
| Alveolar soft part sarcoma (n = 11) | Yes | 81.8 |
| Aneurysmal bone cyst (n = 13) | No | — |
| Angiosarcoma (n = 10) | Yes | 50.0 |
| Blood controls (n = 20) | Yes | 90.0 |
| Chondroblastoma (n = 17) | Yes | 58.8 |
| Chondromyxoid fibroma (n = 14) | No | — |
| CHS, conventional (n = 97) | Yes | 36.1 |
| CHS, clear cell (n = 7) | Yes | 14.3 |
| CHS, mesenchymal (n = 8) | Yes | 87.5 |
| Chordoma (n = 88) | Yes | 85.2 |
| Epithelioid sarcoma (n = 8) | Yes | 62.5 |
| Fibrous dysplasia (n = 6) | Yes | 83.3 |
| Giant cell tumour of bone (n = 57) | Yes | 70.2 |
| Leiomyosarcoma (n = 6) | Yes | 50.0 |
| MPNST (n = 79) | Yes | 25.3 |
| Myxofibrosarcoma (n = 56) | Yes | 42.9 |
| Neurofibroma (n = 6) | Yes | 16.7 |
| Non‐ossifying fibroma (n = 13) | No | — |
| Normal bone (n = 9) | No | — |
| Normal muscle (n = 5) | Yes | 80.0 |
| Normal tissue, NOS (n = 15) | Yes | 60.0 |
| Osteoblastoma (n = 12) | Yes | 75.0 |
| OS, high‐grade central (n = 198) | Yes | 55.1 |
| OS, parosteal, (n = 25) | No | — |
| OS, extraskeletal (n = 18) | No | — |
| PEComa (n = 8) | No | — |
| Phosphaturic mesenchymal tumour (n = 7) | No | — |
| Pleomorphic liposarcoma (n = 14) | Yes | 28.6 |
| Rhabdomyosarcoma (n = 7) | Yes | 57.1 |
| Undifferentiated pleomorphic sarcoma (n = 79) | Yes | 51.9 |
Overview of the sarcoma subtypes with more than five samples included in this study. The full list of samples and subtypes included can be found in supplementary material, Table S1. Subtypes not represented in the DKFZ Classifier were included to demonstrate how the classifier handled subtypes for which it was not yet trained. Dedifferentiated CHSs are included under the conventional CHS category.
NOS, not otherwise specified; PEComa, perivascular epithelioid cell tumour; CHS, chondrosarcoma.